JP5150855B2 - Ｃｄｃａ１−ｋｎｔｃ２複合体を標的とするスクリーニングおよびｎｓｃｌｃの治療方法 - Google Patents

Ｃｄｃａ１−ｋｎｔｃ２複合体を標的とするスクリーニングおよびｎｓｃｌｃの治療方法 Download PDF

Info

Publication number
JP5150855B2
JP5150855B2 JP2008503299A JP2008503299A JP5150855B2 JP 5150855 B2 JP5150855 B2 JP 5150855B2 JP 2008503299 A JP2008503299 A JP 2008503299A JP 2008503299 A JP2008503299 A JP 2008503299A JP 5150855 B2 JP5150855 B2 JP 5150855B2
Authority
JP
Japan
Prior art keywords
cdca1
kntc2
seq
protein
nsclc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008503299A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009505633A (ja
JP2009505633A5 (https=
Inventor
祐輔 中村
弥太郎 醍醐
修一 中鶴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of JP2009505633A publication Critical patent/JP2009505633A/ja
Publication of JP2009505633A5 publication Critical patent/JP2009505633A5/ja
Application granted granted Critical
Publication of JP5150855B2 publication Critical patent/JP5150855B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2008503299A 2005-07-29 2006-07-19 Ｃｄｃａ１−ｋｎｔｃ２複合体を標的とするスクリーニングおよびｎｓｃｌｃの治療方法 Expired - Fee Related JP5150855B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70370405P 2005-07-29 2005-07-29
US60/703,704 2005-07-29
PCT/JP2006/314715 WO2007013480A2 (en) 2005-07-29 2006-07-19 Screening and therapeutic method for nsclc targeting cdca1-kntc2 complex

Publications (3)

Publication Number Publication Date
JP2009505633A JP2009505633A (ja) 2009-02-12
JP2009505633A5 JP2009505633A5 (https=) 2009-09-10
JP5150855B2 true JP5150855B2 (ja) 2013-02-27

Family

ID=37434044

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008503299A Expired - Fee Related JP5150855B2 (ja) 2005-07-29 2006-07-19 Ｃｄｃａ１−ｋｎｔｃ２複合体を標的とするスクリーニングおよびｎｓｃｌｃの治療方法

Country Status (5)

Country Link
US (2) US7943295B2 (https=)
EP (1) EP1915622A2 (https=)
JP (1) JP5150855B2 (https=)
CN (1) CN101283279A (https=)
WO (1) WO2007013480A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100184047A1 (en) * 2007-03-30 2010-07-22 Oncotherapy Science, Inc. Screening and therapeutic method for nsclc targeting the cdca8-aurkb complex
PT2186889E (pt) * 2007-08-20 2015-06-17 Oncotherapy Science Inc Péptido cdca1 e agente farmacêutico que o compreende
GB0719367D0 (en) 2007-10-03 2007-11-14 Procarta Biosystems Ltd Transcription factor decoys, compositions and methods
TWI526219B (zh) * 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
GB201002413D0 (en) 2010-02-12 2010-03-31 Procarta Biosystems Ltd Nucleic acid complexes
GB201005545D0 (en) 2010-04-01 2010-05-19 Procarta Biosystems Ltd Transcription factor decoys
EP2872532A4 (en) 2012-07-10 2016-04-13 Oncotherapy Science Inc CDCA1-EPITOPPEPTIDES FOR TH1 CELLS AND VACCINES THEREWITH
TWI658049B (zh) 2013-03-12 2019-05-01 腫瘤療法 科學股份有限公司 Ｋｎｔｃ２胜肽及含此胜肽之疫苗
JP6700512B2 (ja) 2014-08-04 2020-05-27 オンコセラピー・サイエンス株式会社 Ｃｄｃａ１由来ペプチドおよびそれを含むワクチン
TW202023581A (zh) 2018-08-02 2020-07-01 日商腫瘤療法 科學股份有限公司 來自cdca1的胜肽及含有此的疫苗

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004500029A (ja) * 1999-06-30 2004-01-08 コリクサ　コーポレイション 肺癌の治療および診断のための組成物および方法
US20020172952A1 (en) * 1999-06-30 2002-11-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030211510A1 (en) * 1999-06-30 2003-11-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
WO2002004514A2 (en) * 2000-07-11 2002-01-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
WO2003077875A2 (en) * 2002-03-15 2003-09-25 Incyte Corporation Proteins associated with growth, differentiation, and death
DE60327786D1 (de) 2002-09-12 2009-07-09 Oncotherapy Science Inc Kdr-peptide und diese enthaltende impfstoffe
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
AU2003295328A1 (en) * 2002-10-02 2004-04-23 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
GB0306085D0 (en) * 2002-12-04 2003-04-23 Unilever Plc Improved composition for topical application
AU2003300680A1 (en) 2002-12-10 2004-07-09 Centre National De La Recherche Scientifique Cnrs Thap proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation
WO2004065577A2 (en) * 2003-01-14 2004-08-05 Bristol-Myers Squibb Company Polynucleotides and polypeptides associated with the nf-kb pathway
JP2006523456A (ja) 2003-04-15 2006-10-19 アバロン ファーマシューティカルズ，インコーポレイテッド 分子細胞遺伝学的方法を用いる癌連鎖遺伝子および治療標的の確認
US7339051B2 (en) * 2003-04-28 2008-03-04 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (SARS)
WO2005019258A2 (en) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP2520652B1 (en) * 2004-04-09 2015-06-10 Genecare Research Institute Co., Ltd Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associates genes
AU2006234897A1 (en) * 2005-03-16 2006-10-19 Sidney Kimmel Cancer Center Methods and compositions for predicting death from cancer and prostate cancer survival using gene expression signatures
PT2186889E (pt) 2007-08-20 2015-06-17 Oncotherapy Science Inc Péptido cdca1 e agente farmacêutico que o compreende

Also Published As

Publication number Publication date
WO2007013480A3 (en) 2007-06-28
JP2009505633A (ja) 2009-02-12
WO2007013480A2 (en) 2007-02-01
EP1915622A2 (en) 2008-04-30
US20090215683A1 (en) 2009-08-27
US7943295B2 (en) 2011-05-17
US20110263012A1 (en) 2011-10-27
CN101283279A (zh) 2008-10-08

Similar Documents

Publication Publication Date Title
JP4921522B2 (ja) 非小細胞肺癌の診断のための方法
US20110152345A1 (en) Ebi3, dlx5, nptx1 and cdkn3 for target genes of lung cancer therapy and diagnosis
US20110263012A1 (en) Screening and therapeutic method for nsclc targeting cdca1-kntc2 complex
WO2011096210A1 (en) Prmt1 and prmt6 for target genes of cancer therapy and diagnosis
JP2010536367A (ja) 癌関連遺伝子、ｃｄｃａ５、ｅｐｈａ７、ｓｔｋ３１及びｗｄｈｄ１
JP5640263B2 (ja) Ｄｅｐｄｃ１ポリペプチドを使用した膀胱癌の治療または予防のための方法
US20100184047A1 (en) Screening and therapeutic method for nsclc targeting the cdca8-aurkb complex
US20110014615A1 (en) METHOD FOR DIAGNOSING NON-SMALL CELL LUNG CANCERS BY tRNA-DIHYDROURIDINE SYNTHASE ACTIVITY OF URLC8
US20120010266A1 (en) Tbc1d7 as tumor marker and therapeutic target for cancer
JP2010501162A (ja) 肺癌の治療標的及び予後指標としてのｉｍｐ−１癌遺伝子
WO2012023290A1 (en) Rasef as tumor marker and therapeutic target for cancer
JP2012501166A (ja) 乳癌関連遺伝子ｒｑｃｄ１
JP2013542711A (ja) がんの治療および診断の標的遺伝子としてのＣ６ｏｒｆ１６７
WO2012023284A1 (en) Lhx4 as a target gene for cancer therapy and diagnosis
WO2008020653A1 (en) Use of holliday junction-recognizing protein related to cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090717

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090717

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20120126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120405

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20121015

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121026

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151214

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees